28
Apr

Shares of OncoGenex went into meltdown mode this morning after the biotech and its partner Teva put out word that their experimental prostate cancer drug had flunked a long-awaited Phase III study. Shares of OncoGenex immediately shed more than half their value in the reckoning with investors.

…read more

Source: OncoGenex, Teva flag a failed PhIII for prostate cancer drug

    

0 No comments